New drug Repatha that stop heart attacks doesn’t attract Wall Street investors The new life saving drug Repatha from Amgen, showing to reduce risk of heart attacks and strokes with more than 20% and people with heart disease, getting great reviews from doctors and patients, but still what group not interested – investors.